



www.genfit.com

GENFIT: ADMISSION OF NEW SHARES FOLLOWING THE IMPLEMENTATION OF THE THIRD, FOURTH, AND FIFTH INSTALLMENTS OF THE RESERVED CONVERTIBLE BOND LOAN AGREEMENT OF €8 M

- **Admission of 27,535 new shares corresponding to the payment in shares of the commitment fees of the third, fourth, and fifth installments of the convertible bond loan.**
- **Admission of 34,637 new shares corresponding to the conversion of 20 OCA2012-2 bonds resulting from the implementation of the fourth bond installment.**

Lille (France), Boston (Massachusetts, United States), March 8th, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that 62,172 new shares will shortly be admitted to market trading. These new shares correspond to the payment in shares of the commitment fees linked to the implementation of the third, fourth, and fifth installments of the €8 M bond loan agreement, convertible into ordinary Company shares, signed on December 20th, 2012, as well as the conversion into shares of 20 bonds of the fourth installment, in keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders' Meeting of December 18th, 2012 ("the Assembly").

The Management Board having decided to implement these three €1 M installments of the bond loan agreement, a commitment fee of approximately 5% of the amount of each installment (three times €50,000), has been paid to the Bondholder in ordinary Company shares as follows:

- For the commitment fee of the third installment (see Company press release of February 13, 2013): with an issue price of €4.63, issue premium included, that is, in keeping with the 2nd resolution of the Assembly, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (February 4-8, 2013) prior to the decision to implement this third bond installment. As a result, 10,804 new shares immediately assimilated with existing shares have been subscribed by the Bondholder to offset this commitment fee.
- For the commitment fee of the fourth installment: with an issue price of €6.12, issue premium included, that is, in keeping with the 2nd resolution of the Assembly, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (February 8-14, 2013) prior to the decision to implement this fourth bond installment. As a result, 8,170 new shares immediately assimilated with existing shares have been subscribed by the Bondholder to offset this commitment fee.
- For the commitment fee of the fifth installment: with an issue price of €5.84, issue premium included, that is, in keeping with the 2nd resolution of the Assembly, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (February 20-26, 2013) prior to the decision to implement this fifth bond installment. As a result, 8,561 new shares immediately assimilated with existing shares have been subscribed by the Bondholder to offset this commitment fee.

On March 6th and 8th, 2013, in keeping with the 1st and 2nd resolutions of the Assembly and with the convertible loan contract, the Bondholder requested the conversion of a total of 20 OCA2012-2 bonds resulting from the implementation of the fourth bond installment.

The conversion on March 6th, 2013, of 10 OCA2012-2 bonds into 17,180 new shares was performed at a conversion rate of €5.82, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (February 27 – March 5, 2013) prior to the conversion request.

The conversion on March 8th, 2013, of 10 OCA2012-2 bonds into 17,457 new shares was performed at a conversion rate of €5.73, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (March 1-7, 2013) prior to the conversion request.

As a result of the two share issues reserved to the Bondholder corresponding to the payment in shares of the commitment fees of the fourth and fifth installments of the convertible bond loan, as well as the conversion of bonds emitted as part of the fourth installment, that took place on February 25, 2013 (20 OCA2012-2 bonds converted into 42,958 new shares at a conversion rate of €5.82, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (February 18-22, 2013) prior to the conversion request), and on March 6th and 8th, 2013:

- The social capital of GENFIT has increased from €4,231,979 to €4,255,560.50;
- The number of shares representing the social capital of GENFIT has increased by 94,326, from 16,927,916 à 17,022,242 shares;
- The fourth installment of the bond loan agreement has been completely repaid.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr